Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug.
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the company.
Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Mixed Q3 2025 Results with Revenue Beat but Wider-Than-Expected Loss Arrowhead Pharmaceuticals reported mixed Q3 2025 results, beating revenue estimates but missing on EPS. Stock fell 5.3% as higher R&D costs widened losses. Key pipeline updates include plozasiran NDA submission and Phase 3 trial progress.
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? Stock of Sarepta Therapeutics Inc. (
NASDAQ: SRPT ) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug Administration's (FDA) recommendation to lift the voluntary hold on Elevidys, Sarepta's gene therapy for Duchenne Muscular Dystrophy.
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment.
Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy Sarepta and Roche face a regulatory setback as the EMA's CHMP issues a negative opinion on Elevidys for Duchenne muscular dystrophy patients.
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe Shares are down another double-digit percentage after bad news continued piling on for gene therapy Elevidys.
Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter.
Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' Arrowhead Pharmaceuticals, Snowflake, Dover and Fluor are each in focus on today's edition of "Mad Money Lightning Round."
Which stocks are moving after the closing bell on Monday? The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.
